549 related articles for article (PubMed ID: 19393842)
21. Besifloxacin ophthalmic suspension for bacterial conjunctivitis.
Nafziger AN; Bertino JS
Drugs Today (Barc); 2009 Aug; 45(8):577-88. PubMed ID: 19927224
[TBL] [Abstract][Full Text] [Related]
22. A phase III clinical trial of 0.5% levofloxacin ophthalmic solution versus 0.3% ofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis.
Schwab IR; Friedlaender M; McCulley J; Lichtenstein SJ; Moran CT;
Ophthalmology; 2003 Mar; 110(3):457-65. PubMed ID: 12623805
[TBL] [Abstract][Full Text] [Related]
23. Microbiological efficacy of a new ophthalmic formulation of moxifloxacin dosed twice-daily for bacterial conjunctivitis.
Tauber S; Cupp G; Garber R; Bartell J; Vohra F; Stroman D
Adv Ther; 2011 Jul; 28(7):566-74. PubMed ID: 21681652
[TBL] [Abstract][Full Text] [Related]
24. Phase 3 safety comparisons for 1.0% azithromycin in polymeric mucoadhesive eye drops versus 0.3% tobramycin eye drops for bacterial conjunctivitis.
Protzko E; Bowman L; Abelson M; Shapiro A;
Invest Ophthalmol Vis Sci; 2007 Aug; 48(8):3425-9. PubMed ID: 17652708
[TBL] [Abstract][Full Text] [Related]
25. Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections.
Silverstein BE; Morris TW; Gearinger LS; Decory HH; Comstock TL
Clin Ophthalmol; 2012; 6():1987-96. PubMed ID: 23233796
[TBL] [Abstract][Full Text] [Related]
26. Gatifloxacin 0.5% administered twice daily for the treatment of acute bacterial conjunctivitis in patients one year of age or older.
Heller W; Cruz M; Bhagat YR; De Leon JM; Felix C; Villanueva L; Hollander DA; Jensen H
J Ocul Pharmacol Ther; 2014 Dec; 30(10):815-22. PubMed ID: 25244402
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of clinical efficacy and safety of tobramycin/dexamethasone ophthalmic suspension 0.3%/0.05% compared to azithromycin ophthalmic solution 1% in the treatment of moderate to severe acute blepharitis/blepharoconjunctivitis.
Torkildsen GL; Cockrum P; Meier E; Hammonds WM; Silverstein B; Silverstein S
Curr Med Res Opin; 2011 Jan; 27(1):171-8. PubMed ID: 21138337
[TBL] [Abstract][Full Text] [Related]
28. Ocular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humans.
Proksch JW; Granvil CP; Siou-Mermet R; Comstock TL; Paterno MR; Ward KW
J Ocul Pharmacol Ther; 2009 Aug; 25(4):335-44. PubMed ID: 19492955
[TBL] [Abstract][Full Text] [Related]
29. A randomized, investigator- masked clinical trial comparing the efficacy and safety of gatifloxacin 0.3% administered BID versus QID for the treatment BID versus QID for the treatment of acute bacterial conjunctivitis of acute bacterial conjunctivitis.
Yee RW; Tepedino M; Bernstein P; Jensen H; Schiffman R; Whitcup SM;
Curr Med Res Opin; 2005 Mar; 21(3):425-31. PubMed ID: 15811211
[TBL] [Abstract][Full Text] [Related]
30. A clinical comparison of two formulations of tobramycin 0.3% eyedrops in the treatment of acute bacterial conjunctivitis.
Kernt K; Martinez MA; Bertin D; Stroman D; Cupp G; Martínez C; Tirado M; Guasch J;
Eur J Ophthalmol; 2005; 15(5):541-9. PubMed ID: 16167284
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and Safety of 0.6% Pazufloxacin Ophthalmic Solution Versus Moxifloxacin 0.5% and Gatifloxacin 0.5% in Subjects with Bacterial Conjunctivitis: A Randomized Clinical Trial.
Baiza-Durán L; Olvera-Montaño O; Mercado-Sesma AR; Oregon-Miranda AA; Lizárraga-Corona A; Ochoa-Tabares JC; Pérez-Balbuena AL; Montoya-Sánchez IM; Saucedo-Rodríguez LR; Mora-González A; Gómez-Bastar PA; Villanueva-Najera MA; Sandoval-Delgadillo LI; González-Lomelí M; Páez-Garza JH; Orozco-Carroll M; Casillas-Magallanes M
J Ocul Pharmacol Ther; 2018 Apr; 34(3):250-255. PubMed ID: 29624493
[TBL] [Abstract][Full Text] [Related]
32. Ocular pharmacokinetics/pharmacodynamics of besifloxacin, moxifloxacin, and gatifloxacin following topical administration to pigmented rabbits.
Proksch JW; Ward KW
J Ocul Pharmacol Ther; 2010 Oct; 26(5):449-58. PubMed ID: 20874668
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of besifloxacin in a rabbit model of methicillin-resistant Staphylococcus aureus keratitis.
Sanders ME; Norcross EW; Moore QC; Shafiee A; Marquart ME
Cornea; 2009 Oct; 28(9):1055-60. PubMed ID: 19724203
[TBL] [Abstract][Full Text] [Related]
34. Topical lomefloxacin 0.3% twice daily versus tobramycin 0.3% in acute bacterial conjunctivitis: A multicenter double-blind phase III study.
Gallenga PE; Lobefalo L; Colangelo L; Della Loggia G; Orzalesi N; Velati P; Bujtar E; Ponte F; Damiani S; Bucci MG; Bonini S; Curatola MR; Palma LA; Bonomi L; Tomazzoli Gerosa L; Pagliarusco A; Milan E; Jauch A
Ophthalmologica; 1999; 213(4):250-7. PubMed ID: 10420109
[TBL] [Abstract][Full Text] [Related]
35. Besifloxacin in the management of bacterial infections of the ocular surface.
Deschênes J; Blondeau J
Can J Ophthalmol; 2015 Jun; 50(3):184-91. PubMed ID: 26040217
[TBL] [Abstract][Full Text] [Related]
36. Safety and tolerability of loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension in pediatric subjects.
Comstock TL; Paterno MR; Bateman KM; Decory HH; Gearinger M
Paediatr Drugs; 2012 Apr; 14(2):119-30. PubMed ID: 22292487
[TBL] [Abstract][Full Text] [Related]
37. A Prospective, Randomized Trial of Povidone-Iodine 0.6% and Dexamethasone 0.1% Ophthalmic Suspension for Acute Bacterial Conjunctivitis.
Ta CN; Raizman MB; Gross RD; Joshi S; Mallick S; Wang Y; Segal B
Am J Ophthalmol; 2020 Jul; 215():56-65. PubMed ID: 32222367
[TBL] [Abstract][Full Text] [Related]
38. Loteprednol etabonate ophthalmic gel 0.5% following cataract surgery: integrated analysis of two clinical studies.
Rajpal RK; Fong R; Comstock TL
Adv Ther; 2013 Oct; 30(10):907-23. PubMed ID: 24136301
[TBL] [Abstract][Full Text] [Related]
39. Once-daily ofloxacin otic solution versus neomycin sulfate/polymyxin B sulfate/hydrocortisone otic suspension four times a day: a multicenter, randomized, evaluator-blinded trial to compare the efficacy, safety, and pain relief in pediatric patients with otitis externa.
Schwartz RH
Curr Med Res Opin; 2006 Sep; 22(9):1725-36. PubMed ID: 16968576
[TBL] [Abstract][Full Text] [Related]
40. Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: microbiological eradication outcomes.
Morris TW; Gearinger LS; Usner DW; Paterno MR; Decory HH; Comstock TL; Haas W
Clin Ophthalmol; 2011; 5():1359-67. PubMed ID: 22034555
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
